Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500868 | 0.89 | PTGS2 (0.33) | — | |
| SCHEMBL6497641 | 0.73 | PTGS2 (0.39) | CNR2 | |
| SCHEMBL6501963 | 0.70 | CCKBR (0.56) | — | |
| SCHEMBL6064596 | 0.70 | ALDH1A1 (0.37) | CNR2 | |
| SCHEMBL7984023 | 0.68 | PTGS2 (0.36) | CNR2 | |
| SCHEMBL6490137 | 0.68 | PTGS2 (0.38) | CNR2 | |
| SCHEMBL6489013 | 0.67 | CCKBR (0.33) | — | |
| SCHEMBL6500948 | 0.66 | PARP1 (0.30) | — | |
| SCHEMBL6065524 | 0.65 | CNR2 (0.37) | CNR2 | |
| SCHEMBL6330195 | 0.57 | CCKBR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956053-B2 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2005-10-18 | — | — | US | disclosed |
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | JAMES BLACK FOUNDATION LIMITED, THE (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | CCKBR, GRPR, CCKAR | CNR2 112/4885PDE4A 3588/4885PDE4B 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.